Polymeric nanoparticles for the delivery of miRNA to treat Chronic Obstructive Pulmonary Disease (COPD)

被引:47
作者
Mohamed, Adel [1 ]
Kunda, Nitesh K. [2 ]
Ross, Kehinde [1 ]
Hutcheon, Gillian A. [1 ]
Saleem, Imran Y. [1 ]
机构
[1] Liverpool John Moores Univ, Sch Pharm & Biomol Sci, Byrom St, Liverpool L3 3AF, Merseyside, England
[2] St Johns Univ, Dept Pharmaceut Sci, Coll Pharm & Hlth Sci, Jamaica, NY 11439 USA
关键词
Nanoparticles; microRNA (miRNA); miR-146a; Chronic Obstructive Pulmonary Disease (COPD); Interleukin-1 receptor-associated kinase 1 (IRAK1); RNA interference (RNAi); Inflammation; PLGA NANOPARTICLES; NONVIRAL VECTORS; MICRORNAS; RNA; NANOSPHERES; FORMULATION; PROTEINS; DOMINANT; MODULATE; VACCINE;
D O I
10.1016/j.ejpb.2019.01.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) based therapeutics are considered an endogenous mechanism for modulating gene expression. In addition, microRNAs (miRNAs) may be tractable targets for the treatment of Chronic Obstructive Pulmonary Disease (COPD). In this study miR146a was adsorbed onto poly (glycerol adipate-co-omega-pentadecalactone), PGA-co-PDL, nanoparticles (NPs) to reduce target gene IRAK1 expression. NPs were prepared using an oil-in-water single emulsion solvent evaporation method incorporating cationic lipid dioleoyl-trimethylammoniumpropane (DOTAP). This resulted in NPs of 244.80 +/- 4.40 nm at 15% DOTAP concentration, zeta potential (ZP) of + 14.8 +/- 0.26 mV and miR-146a (40 mu g/ml) maximum adsorption onto 15% DOTAP NPs was 36.25 +/- 0.35 mu g per 10 mg NP following 24 h incubation. Using the MTT assay, it was observed that over 75% at 0.312 mg/ml of A549 cells remained viable after 18 h exposure to cationic NPs at a concentration of 1.25 mg/ml. Furthermore, the in vitro release profile of miR-146a from loaded NPs showed a continuous release up to 77% after 24 h. Internalization of miR-146a loaded cationic NPs was observed in A549 cell lines using fluorescence and confocal microscopy. The miR146a delivered as miR-146a-NPs had a dose dependent effect of highest NPs concentrations 0.321 and 0.625 mg/ml and reduced target gene IRAK1 expression to 40%. In addition, IL-8 promoter reporter output (GFP) was dampened by miR-146a-NPs. In conclusion, miR-146a was successfully adsorbed onto PGA-co-PDL-DOTAP NPs and the miR-146a retained biological activity. Therefore, these results demonstrate the potential of PGA-co-PDL NPs as a delivery system for miR-146a to treat COPD.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [21] Cellular effectors of the inflammatory response in chronic obstructive pulmonary disease (COPD)
    Silva O., Rafael
    Montes, Juan F.
    Garcia-Valero, Jose
    Olloquequi, Jordi
    REVISTA MEDICA DE CHILE, 2015, 143 (09) : 1162 - 1171
  • [22] Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies
    Biener, L.
    Pizarro, C.
    Skowasch, D.
    INNERE MEDIZIN, 2024, 65 (07): : 738 - 745
  • [23] Bronchoscopic treatments of chronic obstructive pulmonary disease (COPD): a narrative review
    Saeed, Hasham
    Dibardino, David M.
    Ma, Kevin C.
    AME MEDICAL JOURNAL, 2024, 9
  • [24] Investigation of the role of miRNAs as a biomarker in chronic obstructive pulmonary disease (COPD)
    Akbas, Fahri
    Coskunpinar, Ender
    Aynaci, Engin
    Oltulu, Yasemin Musteri
    Yildiz, Pinar
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [25] Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD)
    Thomas, Biju
    Koh, Mariko Siyue
    O'Callaghan, Christopher
    Allen, John Carson, Jr.
    Rutman, Andrew
    Hirst, Robert Anthony
    Connolly, John
    Low, Su Ying
    How, Ong Thun
    Min, Loo Chian
    Lim, Wan Teck
    Oon, Lynette Lin Ean
    He, Qixian
    Teoh, Oon Hoe
    Lapperre, Therese Sophie
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 18 (06) : 657 - 663
  • [26] Inhalation treatment of chronic obstructive pulmonary disease (COPD) in older patients
    Stenmanns, Carla
    Frohnhofen, Helmut
    Muenks-Lederer, Claudia
    Matthes, Sandhya
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2025, 58 (02): : 97 - 102
  • [27] Controlled breathing and dyspnea in patients with chronic obstructive pulmonary disease (COPD)
    Gosselink, R
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2003, 40 (05) : 25 - 33
  • [28] Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease
    Cazzola, Mario
    Cavalli, Francesco
    Usmani, Omar S.
    Rogliani, Paola
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (05) : 635 - 646
  • [29] Therapeutic prospects to treat skeletal muscle wasting in COPD (chronic obstructive lung disease)
    Hansen, MJ
    Gualano, RC
    Bozinovski, S
    Vlahos, R
    Anderson, GP
    PHARMACOLOGY & THERAPEUTICS, 2006, 109 (1-2) : 162 - 172
  • [30] Altered miRNA expression in lung tissues of patients with chronic obstructive pulmonary disease
    Kim, Woo Jin
    Lim, Jae Hyun
    Hong, Yoonki
    Hong, Seok-Ho
    Bang, Chi Young
    Lee, Jae Seung
    Oh, Yeon-Mok
    Kim, Ju Han
    MOLECULAR & CELLULAR TOXICOLOGY, 2017, 13 (02) : 207 - 212